PuraPharm Corporation Ltd - Shs Reg S

HKSE:01498 (Hong Kong)   Shs Reg S
HK$ 0.77 (+2.67%) May 3
At Loss
P/B:
1.97
Market Cap:
HK$ 304.84M ($ 39.04M)
Enterprise V:
HK$ 701.57M ($ 89.85M)
Volume:
54.00K
Avg Vol (2M):
73.15K
Volume:
54.00K
At Loss
Avg Vol (2M):
73.15K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for PuraPharm Corporation Ltd ( ) from 2015 to May 03 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. PuraPharmoration stock (HKSE:01498) PE ratio as of May 03 2024 is 0. More Details

PuraPharm Corporation Ltd (HKSE:01498) PE Ratio (TTM) Chart

To

PuraPharm Corporation Ltd (HKSE:01498) PE Ratio (TTM) Historical Data

Total 1199
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
PuraPharmoration PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-03 At Loss 2024-02-26 At Loss
2024-05-02 At Loss 2024-02-23 At Loss
2024-04-30 At Loss 2024-02-22 At Loss
2024-04-29 At Loss 2024-02-21 At Loss
2024-04-26 At Loss 2024-02-20 At Loss
2024-04-25 At Loss 2024-02-19 At Loss
2024-04-24 At Loss 2024-02-16 At Loss
2024-04-23 At Loss 2024-02-15 At Loss
2024-04-22 At Loss 2024-02-14 At Loss
2024-04-19 At Loss 2024-02-09 At Loss
2024-04-18 At Loss 2024-02-08 At Loss
2024-04-17 At Loss 2024-02-07 At Loss
2024-04-16 At Loss 2024-02-06 At Loss
2024-04-15 At Loss 2024-02-05 At Loss
2024-04-12 At Loss 2024-02-02 At Loss
2024-04-11 At Loss 2024-02-01 At Loss
2024-04-10 At Loss 2024-01-31 At Loss
2024-04-09 At Loss 2024-01-30 At Loss
2024-04-08 At Loss 2024-01-29 At Loss
2024-04-05 At Loss 2024-01-26 At Loss
2024-04-03 At Loss 2024-01-25 At Loss
2024-04-02 At Loss 2024-01-24 At Loss
2024-03-28 At Loss 2024-01-23 At Loss
2024-03-27 At Loss 2024-01-22 At Loss
2024-03-26 At Loss 2024-01-19 At Loss
2024-03-25 At Loss 2024-01-18 At Loss
2024-03-22 At Loss 2024-01-17 At Loss
2024-03-21 At Loss 2024-01-16 At Loss
2024-03-20 At Loss 2024-01-15 At Loss
2024-03-19 At Loss 2024-01-12 At Loss
2024-03-18 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-22 At Loss
2024-02-29 At Loss 2023-12-21 At Loss
2024-02-28 At Loss 2023-12-20 At Loss
2024-02-27 At Loss 2023-12-19 At Loss

PuraPharm Corporation Ltd (HKSE:01498) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.